Ohr Pharmaceutical Inc. is a pharmaceutical company dedicated to the clinical development of new drugs for underserved therapeutic needs in large and growing markets. The Company is focused on advancing its pipeline products currently in Phase 2 clinical development: Squalamine Eye Drops for the treatment of the wet form of age-related macular degeneration, and OHR/AVR118 for the treatment of cancer cachexia.
800 Third Avenue
New York, NY 10022
Jason Slakter M.D.
Pharmaceutical Preparation Manufacturing (325412)
Pharmaceutical Preparations (2834)